Search hospitals > Virginia > Lynchburg
Centra Lynchburg Hematology-Oncology Clinic Inc
Claim this profileLynchburg, Virginia 24501
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
103 reported clinical trials
11 medical researchers
Summary
Centra Lynchburg Hematology-Oncology Clinic Inc is a medical facility located in Lynchburg, Virginia. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Centra Lynchburg Hematology-Oncology Clinic Inc is involved with conducting 103 clinical trials across 148 conditions. There are 11 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Erin R. Alesi, and Khalid Matin.Area of expertise
1Cancer
Global LeaderStage III
Stage IV
Stage II
2Lung Cancer
Global LeaderStage III
Stage II
Stage IV
Top PIs
Andrew Poklepovic, MDVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Expert in Cancer
Expert in Tumors
33 reported clinical trials
82 drugs studied
Sarah W. Gordon, DOVirginia Commonwealth University/Massey Cancer Center7 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
26 reported clinical trials
54 drugs studied
Erin R. AlesiVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
12 reported clinical trials
19 drugs studied
Khalid MatinVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
13 reported clinical trials
29 drugs studied
Clinical Trials running at Centra Lynchburg Hematology-Oncology Clinic Inc
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma
Multiple Myeloma
Skin Cancer
Cutaneous Melanoma
Laryngeal Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Symptom Monitoring
for Young Women on Hormone Therapy
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
T-DM1 + Tucatinib
for Breast Cancer
This study is evaluating whether a combination of two drugs may help prevent breast cancer from coming back.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Centra Lynchburg Hematology-Oncology Clinic Inc?
Centra Lynchburg Hematology-Oncology Clinic Inc is a medical facility located in Lynchburg, Virginia. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Centra Lynchburg Hematology-Oncology Clinic Inc is involved with conducting 103 clinical trials across 148 conditions. There are 11 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Erin R. Alesi, and Khalid Matin.